Dr. Richard Furman, a leading CLL clinician and researcher at Weill-Cornell Medical College, attended the International Workshop on CLL in Germany and came away with a firm resolve not to prescribe chemotherapy regimens for his patients. With new medicines nearing expected FDA approval, Dr. Furman explains how a leading treatment candidate, Ibrutinib, works. He also discusses whether there is concern that some patients may develop resistance to the drug and its effectiveness.
Get email alerts | http://www.patientpower.info/
Subscribe on YouTube | http://bit.ly/patientpowerYT
Like on Facebook | http://www.fb.com/patientpower.info
Follow on Twitter | http://www.twitter.com/patientpower
){kind=link}
Comments